CoChat

The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells

Open access
Lu, Min, Xia, Lijuan, Li, Yan, Wang, Xiaoli, Hoffman, Ronald · 2014 · Blood
Cited by 68

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Key Points: Combination treatment with RG7112 and Peg-IFNα 2a targets primitive JAK2V617F+ progenitor cells in myeloproliferative neoplasms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2013-11-536854

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • MDM2 inhibitors for cancer therapy

    Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · cited 1×

    “The cis-imidazoline compounds termed nutlins were the first potent and selective MDM2 inhibitors, and their discovery stimulated widespread interest in the design of small molecule p53-MDM2 inhibitors.(22,25) We reported that combination treatment with low doses of Peg IFNa 2a and nutlin-3, an antagonist of”
    Background

Show all 1 references

Cited by

See all 68

Metadata

Authors
Lu, M., Xia, L., Li, Y., Wang, X., & Hoffman, R.
Venue
Blood
Published
2014-07-31
Volume
124
Issue
5
Pages
771-779
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2131752437
Cited by
68
References
1
FWCI
1.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. https://app.cochat.ai/papers/10.1182/blood-2013-11-536854
The paper
Lu, M., Xia, L., Li, Y., Wang, X., & Hoffman, R. (2014). The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood. https://doi.org/10.1182/blood-2013-11-536854

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.